2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 74, n° 1
pages 177-179 (janvier 2016)
Doi : 10.1016/j.jaad.2015.08.010
Research Letters

Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment

Juul M.P.A. van den Reek, MD a, , Philippe A.R.R. Pijls, MD b, Marcia Tummers, PhD d, Piet C.L.M. van Riel, MD, PhD c, Wietske Kievit, PhD d, Frank Hoentjen, MD, PhD b, Elke M.G.J. de Jong, MD, PhD a
a Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands 
b Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands 
c Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands 
d Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands 

Correspondence to: Juul M. P. A. van den Reek, MD, Radboud University Medical Center, Department of Gastroenterology/Dermatology, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands

 Juul M. P. A. van den Reek and Philippe A. R. R. Pijls share first authorship.
 Funding sources: The BioCAPTURE registry is Supported by University Medical Centre St Radboud Foundation, which received funding from Pfizer, Janssen, and AbbVie for the project. Pfizer, Janssen, and AbbVie played no role in the design and execution of the study or in data collection, data management, data analysis, interpretation of the data, manuscript preparation, manuscript review, or manuscript approval.
 The registry was approved by our medical ethics committee. According to Dutch law, informed consent was not mandatory for this noninterventional study; however, it is obtained from every newly included patient.
 Conflicts of interest: J.M.P.A. van den Reek carries out clinical trials for AbbVie and Janssen. J.M.P.A. van den Reek has received speaking fees from AbbVie and Eli Lilly and reimbursement for attending symposia from Janssen, Pfizer, and AbbVie. E.M.G.J. de Jong has received research grants for the independent research fund of the Department of Dermatology of the University Medical Center St Radboud, Nijmegen, The Netherlands, from AbbVie, Pfizer, and Janssen, and has acted as a consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Janssen, Pfizer, and Merck, Sharp & Dohme.

Top of the page

© 2015  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline